www.cancertherapyadvisor.com Open in urlscan Pro
2606:4700::6812:3ad  Public Scan

Form analysis
2 forms found in the DOM

https://www.cancertherapyadvisor.com/

<form class="search focus-label" id="mobile-search" aria-hidden="true" action="https://www.cancertherapyadvisor.com/" aria-expanded="false">
  <input class="searchinput predictive-search" id="q" type="text" value="" name="s">
  <label class="searchformlabel " id="q-label" for="q"> Search... </label>
  <button class="submit" type="submit">
    <span class="searchicon">
      <svg role="presentation" class="icon icon--search" aria-label="search">
        <use xlink:href="https://www.cancertherapyadvisor.com/wp-content/themes/haymarket/assets/svg/src.svg?ver=1666876545#search"></use>
      </svg> </span>
    <span class="screen-reader-text">Submit</span>
  </button>
</form>

<form class="HMIRegistration__form ismedical" novalidate="">
  <div class="HMIRegistration__row ">
    <div class="HMIRegistration__column u-col12">
      <div class="HMIRegistration__form-control HMIRegistration__input "><input class="form-control" type="email" id="root_email" label="email" placeholder="*E-mail Address" value=""></div>
    </div>
  </div>
  <div class="HMIRegistration__row ">
    <div class="HMIRegistration__column u-col12">
      <div class="HMIRegistration__form-control HMIRegistration__input "><input class="form-control" type="password" id="root_password" label="password" placeholder="*Password" value=""></div>
    </div>
  </div>
  <div class="HMIRegistration__row ">
    <div class="HMIRegistration__column u-col12">
      <div class="HMIRegistration__checkbox"><span class="HMIRegistration__sprite"><span class="HMIRegistration__sprite-border "></span><span class="HMIRegistration__sprite-checkmark "><svg width="15" height="15" class="widget-svg">
              <path class="checkmark" d="M5.6,13.4C3.7,11.6,1.9,9.8,0,8c0.8-0.8,1.6-1.6,2.3-2.3c1.1,1,2.2,2.1,3.3,3.1c2.4-2.4,4.7-4.8,7-7.2 c0.8,0.8,1.5,1.6,2.3,2.3C11.9,7,8.8,10.2,5.6,13.4z"></path>
            </svg></span><span class="HMIRegistration__sprite-fill "></span></span><span class="HMIRegistration__text ">Keep me signed in</span></div>
    </div>
  </div>
  <p class="HMIRegistration__text linkToForgetPword ismedical"><a href="#" class="HMIRegistration__link ismedical" data-feathr-click-track="true" data-feathr-link-aids="[&quot;5ac50f6bf60e8103ce30c554&quot;]">Forgot your password?</a></p><button
    class="HMIRegistration__submit ismedical" type="submit">Login</button>
  <p class="HMIRegistration__text goToRegister ismedical">
    <a href="#" class="HMIRegistration__link ismedical" data-feathr-click-track="true" data-feathr-link-aids="[&quot;5ac50f6bf60e8103ce30c554&quot;]">Do not have an account yet?<strong> Register</strong></a></p>
</form>

Text Content

Skip to navigation Skip to main content




Menu Close
Search... Submit
 * Breast
 * CML
 * Gastrointestinal
 * GYN
 * Lung
 * Multiple Myeloma
 * Prostate
 * RCC
 * Skin
 * MoreOpen Submenu
   * More Back
      * Bladder Cancer
      * Bone Cancer
      * Brain Cancer
      * Chronic Lymphocytic Leukemia
     
      * Endocrine Cancer
      * General Medicine
      * General Oncology
      * Head and Neck Cancer
      * Hematologic Cancers
     
      * Lymphoma
      * Pancreatic Cancer
      * Pediatric Cancer
      * Practice Management
     
      * Sarcoma
      * Supportive Care
      * Urologic Cancers

Toggle Search Menu
 * Headlines
 * Drugs
 * Conferences
 * Cancer Management
 * Clinical Resources
 * Tools
 * Multimedia
 * CME
 * Jobs

Advertisement


Login Register
 * Get the App
 * Submit Cases

 * 
 * 
 * 


TOP NEWS


MORE CANCER SURVIVORS ARE BEING DIAGNOSED WITH NEW CANCERS


FOLFOXIRI-BEVACIZUMAB DEEMED OPTIMAL FOR CERTAIN PATIENTS WITH CRC LIVER
METASTASES


HDC-ASCT IMPROVES SURVIVAL VS IMMUNOCHEMOTHERAPY IN PRIMARY CNS LYMPHOMA


FOOD-DRUG INTERACTION COULD COMPROMISE EFFICACY OF ALECTINIB


TALZENNA COMBO APPROVED FOR HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT
PROSTATE CANCER


NATIONAL HEALTH SPENDING SET TO INCREASE THROUGH 2031


CHANGES TO PRIMARY ENDPOINTS OF ICI TRIALS ARE NOT BEING DISCLOSED


SUNVOZERTINIB SHOWS ACTIVITY IN NSCLC PATIENTS AFTER PLATINUM CHEMO FAILURE


ACALABRUTINIB PLUS RITUXIMAB “HIGHLY EFFECTIVE” IN OLDER MCL PATIENTS


MORTALITY RATES HAVE DECREASED FOR WOMEN WITH EARLY INVASIVE BREAST CANCER


OUTCOMES OF UNRELATED, HAPLO TRANSPLANT IN AML HAVE IMPROVED OVER TIME


SURVEY: MOST AMERICANS HAVE PROBLEMS WITH THEIR HEALTH INSURANCE PLANS

More  »

EDITORIAL ADVISORY BOARD

Barbara Ann Burtness, MD

Steven Cohen, MD

E. David Crawford, MD

Don S. Dizon, MD, FACP

Jeffrey M. Farma, MD

Neal D. Shore, MD, FACS

Mark A. Socinski, MD

Mario Sznol, MD


Click here for complete profiles





FEATURED

Previous 1 / 6 Next


UPDATE ON BLADDER CANCER RISK FACTORS

A recent review provided an update on traditional and novel risk factors for
bladder cancer that may help guide prevention efforts.


ASCO 2023: STUDIES CLARIFY ROLE OF IMMUNOTHERAPY IN MULTIPLE MYELOMA

Studies from ASCO 2023 revealed new potential standards of care for multiple
myeloma and a first for bispecific antibody therapy.


ICML 2023

News from the International Conference on Malignant Lymphoma


EHA 2023

News from the EHA 2023 Hybrid Congress


ASCO 2023

News from the ASCO Annual Meeting 2023


OPINION: SURGEON COLLABORATION IS KEY TO MITIGATING POST-MASTECTOMY CHEST
NUMBNESS 

Breast surgeons and plastic reconstructive surgeons should work together to care
for nerves in the breasts during breast cancer surgery.


UPDATE ON BLADDER CANCER RISK FACTORS

A recent review provided an update on traditional and novel risk factors for
bladder cancer that may help guide prevention efforts.


ASCO 2023: STUDIES CLARIFY ROLE OF IMMUNOTHERAPY IN MULTIPLE MYELOMA

Studies from ASCO 2023 revealed new potential standards of care for multiple
myeloma and a first for bispecific antibody therapy.


ICML 2023

News from the International Conference on Malignant Lymphoma


EHA 2023

News from the EHA 2023 Hybrid Congress


ASCO 2023

News from the ASCO Annual Meeting 2023


OPINION: SURGEON COLLABORATION IS KEY TO MITIGATING POST-MASTECTOMY CHEST
NUMBNESS 

Breast surgeons and plastic reconstructive surgeons should work together to care
for nerves in the breasts during breast cancer surgery.


UPDATE ON BLADDER CANCER RISK FACTORS

A recent review provided an update on traditional and novel risk factors for
bladder cancer that may help guide prevention efforts.
 * 
 * 
 * 
 * 
 * 
 * 


MORE FEATURES


STATE OF CANCER RESEARCH: IMPACT OF COVID-19, BREXIT, WAR, AND OTHER GLOBAL
EVENTS

By
Victoria Forster, PhD


AACR 2023 HIGHLIGHTS NOVEL RESEARCH IN NSCLC AND ES-SCLC  

By
Tori Rodriguez, MA, LPC, AHC


LACK OF ACCESS TO ABORTION HAS HAD A NEGATIVE IMPACT ON CANCER CARE

By
Tori Rodriguez, MA, LPC, AHC


GLOBAL SURVEY SUGGESTS RCC PATIENTS ARE UNDERINFORMED, FACE OBSTACLES TO CARE

By
Alan P. Lyss, MD


IBRUTINIB NO LONGER APPROVED FOR MCL, MZL: HOW THIS CHANGE WILL AFFECT PATIENTS

By
Mary Ellen Schneider

More Features  »


FACT SHEETS


FACT SHEET: COVID-19 VACCINE CONSIDERATIONS FOR PATIENTS WITH CANCER


WHAT TO EXPECT: ENROLLING ON A CANCER CLINICAL TRIAL DURING COVID-19

More  »

 * Registered users get free access to premium features like:
   
    * A personalized onsite experience
    * Your top three articles, curated onsite daily
    * Unlimited access to our expert content
   
   REGISTER
   
   Already have an account? Sign in here

 * Advertisement
 * Loading...
   
   Popular in Cancer Therapy
   
   siteName Cancer Therapy Advisor siteURL https://www.cancertherapyadvisor.com
   siteID 12 First-Line Pembrolizumab Improves Survival in Metastatic Cervical
   Cancer Colby Stong 5 June 2023 cancertherapyadvisor.com Updated data support
   the use of pembrolizumab in combination with chemotherapy as first-line
   standard care for patients … siteName Cancer Therapy Advisor siteURL
   https://www.cancertherapyadvisor.com siteID 12 Zanidatamab Yields Durable
   Responses in HER2+ Biliary Tract Cancer James Nam, PharmD 4 June 2023
   cancertherapyadvisor.com Zanidatamab can produce rapid and durable responses
   in patients with advanced HER2-positive biliary tract cancer, phase 2 data
   suggest. siteName Cancer Therapy Advisor siteURL
   https://www.cancertherapyadvisor.com siteID 12 Ultrasound Technique Delivers
   Paclitaxel Across Blood-Brain Barrier in Glioblastoma Leah Lawrence 17 May
   2023 cancertherapyadvisor.com An ultrasound technique allows for delivery of
   albumin-bound paclitaxel across the blood-brain barrier in patients with …
   siteName Cancer Therapy Advisor siteURL https://www.cancertherapyadvisor.com
   siteID 12 UCPVax Prompts Immune Responses in MGMT Unmethylated Glioblastoma
   Bryant Furlow 4 June 2023 cancertherapyadvisor.com UCPVax, an anti-telomerase
   vaccine, has demonstrated immunogenicity in a phase 2 trial of patients with
   MGMT unmethylated glioblastoma. siteName Cancer Therapy Advisor siteURL
   https://www.cancertherapyadvisor.com siteID 12 Menstrual Disturbances Not
   Being Tracked, Treated in Cancer Patients  Leah Lawrence 24 April 2023
   cancertherapyadvisor.com New research suggests that some cancer patients do
   not have their menstrual history documented and do not receive treatm…
   siteName Cancer Therapy Advisor siteURL https://www.cancertherapyadvisor.com
   siteID 12 High TMB Associated With Better Outcomes of ICI Therapy in Advanced
   Cancers Leah Lawrence 16 May 2023 cancertherapyadvisor.com Patients with
   advanced cancer have better outcomes if they have high TMB prior to treatment
   with an ICI, new research suggests.
 * Advertisement
 * Loading...
   
   Continuing Medical Education (CME/CE) Courses
   
   siteName Cancer Therapy Advisor siteURL https://www.cancertherapyadvisor.com
   siteID 12 Pearls for Management of Common Pediatric Disorders: Who’s at Risk
   of “Tridemic” Impacts? Haymarket Media 26 May 2023 mycme.com siteName Cancer
   Therapy Advisor siteURL https://www.cancertherapyadvisor.com siteID 12 From
   Recognition to Refractory Care: Management of Pulmonary MAC Haymarket Media 6
   June 2023 mycme.com siteName Cancer Therapy Advisor siteURL
   https://www.cancertherapyadvisor.com siteID 12 Childhood Interstitial Lung
   Diseases: Increasing Awareness, Diagnosis, and Multidisciplinary Patient
   Management Haymarket Media 9 June 2023 mycme.com siteName Cancer Therapy
   Advisor siteURL https://www.cancertherapyadvisor.com siteID 12 Optimizing
   Outcomes in ALS: Best Practices in Screening, Diagnosis, and Treatment
   Haymarket Media 13 June 2023 mycme.com siteName Cancer Therapy Advisor
   siteURL https://www.cancertherapyadvisor.com siteID 12 Rett Syndrome Update:
   Evolving Management Strategies Haymarket Media 1 June 2023 mycme.com siteName
   Cancer Therapy Advisor siteURL https://www.cancertherapyadvisor.com siteID 12
   A New Era in Small Cell Lung Cancer: Progress in Immunotherapy for Extensive
   Stage Disease Haymarket Media 24 May 2023 mycme.com
   
   Show More

 * Advertisement


Back to Top

 * CancerTherapyAdvisor.com is a free online resource that offers oncology
   healthcare professionals a comprehensive knowledge base of practical oncology
   information and clinical tools to assist in making the right decisions for
   their patients.
   
   Our mission is to provide practice-focused clinical and drug information that
   is reflective of current and emerging principles of care that will help to
   inform oncology decisions.

 * Do Not Sell or Share My Personal Information

 * 
 * 
 * 

 * RESOURCES
   
    * Submissions
    * Advisory Board
    * Useful Links
    * Reprints/Permissions

 * USER CENTER
   
    * About Us
    * Advertise
    * Contact Us
    * Staff

 * OTHER HAYMARKET MEDICAL WEBSITES
   
    * Clinical Advisor
    * Clinical Pain Advisor
    * Dermatology Advisor
    * Endocrinology Advisor
    * Gastroenterology Advisor
    * Hematology Advisor
    * Infectious Disease Advisor
    * McKnight’s Long Term Care News
    * McKnight’s Senior Living
    * Medical Bag
    * MPR
    * myCME
    * Neurology Advisor
    * Oncology Nurse Advisor
    * Ophthalmology Advisor
    * Optometry Advisor
    * Psychiatry Advisor
    * Pulmonology Advisor
    * Rare Disease Advisor
    * Renal and Urology News
    * Rheumatology Advisor
    * The Cardiology Advisor

 * Copyright © 2023 Haymarket Media, Inc. All Rights Reserved
   This material may not be published, broadcast, rewritten or redistributed in
   any form without prior authorization.
   Your use of this website constitutes acceptance of Haymarket Media’s Privacy
   Policy and Terms & Conditions.

Some areas of this page may shift around if you resize the browser window. Be
sure to check heading and document order.
Close more info about Home


LOG IN TO CANCER THERAPY ADVISOR




PLEASE LOG IN USING YOUR PASSWORD.

*Required
Keep me signed in

Forgot your password?

Login

Do not have an account yet? Register


Close more info about Home


JOIN THE




CREATING YOUR FREE ACCOUNT WITH CANCER THERAPY ADVISOR ALLOWS YOU ACCESS TO
EXCLUSIVE CONTENT, INCLUDING CASE STUDIES, DRUG INFORMATION, CME AND MORE ACROSS
OUR GROWING NETWORK OF CLINICAL SITES.

*Required
*ProfessionCertified Diabetes EducatorClinical Nurse SpecialistConsumer /
PatientDentistDietitian / NutritionistGenetic CounselorNurseNurse
PractitionerOptometristOther Healthcare ProfessionalPharmacistPhysicianPhysician
AssistantPsychologistResidentSocial WorkerStudent

*SpecialtyAllergy / ImmunologyAnesthesiologyBariatric
MedicineCardiologyComplementary / Alternative MedicineCritical Care
MedicineDentalDermatologyDiabetesEmergency MedicineEndocrinologyFamily Medicine
/ General PracticeGastroenterology / ProctologyGeriatric
MedicineHematologyHematology / OncologyHospitalistInfectious DiseaseInfusion
TherapyInternal MedicineLong-Term CareNephrologyNeurologyNutritionObstetrics /
GynecologyOncologyOphthalmologyOptometryOrthopedicsOtolaryngologyPain
MedicinePathologyPediatricsPharmacyPhysical Medicine /
RehabilitationPsychiatryPublic Health / Preventive MedicinePulmonologyRadiology
/ Nuclear MedicineRheumatologySports MedicineSurgeryUrologyOther

*CountryUnited States

--State--AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew
HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth
DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth
DakotaTennesseeTexasUtahVermontVirginiaWashingtonWashington, D.C.West
VirginiaWisconsinWyoming


REGISTER FOR EMAIL NEWSLETTERS

Cancer Therapy Advisor Weekly Highlights
Cancer Therapy Advisor Daily Update
Register

Already have an account with one of our brands? LOG IN

Terms and Conditions | Privacy Policy



word word word word word word word word word word word word word word word word
word word word word word word word word word word word word word word word word
word word word word word word word word word word word word word word word word
word word word word word word word word word word word word word word word word
word word word word word word word word word word word word word word word word
word word word word word word word word word word word word word word word word
word word word word word word word word word word word word word word word word
word word word word word word word word word word word word word word word word
word word word word word word word word word word word word word word word word
word word word word word word word word word word word word word word word word
word word word word word word word word word word word word word word word word
word word word word word word word word word word word word word word word word
word word word word word word word word

mmMwWLliI0fiflO&1
mmMwWLliI0fiflO&1
mmMwWLliI0fiflO&1
mmMwWLliI0fiflO&1
mmMwWLliI0fiflO&1
mmMwWLliI0fiflO&1
mmMwWLliI0fiflO&1


DO NOT SELL OR SHARE MY PERSONAL DATA

When you visit our website, we store cookies on your browser to collect
information. The information collected might relate to you, your preferences or
your device, and is mostly used to make the site work as you expect it to and to
provide a more personalized web experience. However, you can choose not to allow
certain types of cookies, which may impact your experience of the site and the
services we are able to offer. Click on the different category headings to find
out more and change our default settings according to your preference. You
cannot opt-out of our First Party Strictly Necessary Cookies as they are
deployed in order to ensure the proper functioning of our website (such as
prompting the cookie banner and remembering your settings, to log into your
account, to redirect you when you log out, etc.). For more information about the
First and Third Party Cookies used please follow this link.
More information
Accept


MANAGE CONSENT PREFERENCES

STRICTLY NECESSARY COOKIES

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
which amount to a request for services, such as setting your privacy
preferences, logging in or filling in forms.    You can set your browser to
block or alert you about these cookies, but some parts of the site will not then
work. These cookies do not store any personally identifiable information.

 * FUNCTIONAL COOKIES
   
   Always Active
   
   These cookies enable the website to provide enhanced functionality and
   personalisation. They may be set by us or by third party providers whose
   services we have added to our pages.    If you do not allow these cookies
   then some or all of these services may not function properly.

DO NOT SELL PERSONAL INFORMATION

Do Not Sell Personal Information

 * SOCIAL MEDIA COOKIES
   
   Switch Label label
   
   These cookies are set by a range of social media services that we have added
   to the site to enable you to share our content with your friends and
   networks. They are capable of tracking your browser across other sites and
   building up a profile of your interests. This may impact the content and
   messages you see on other websites you visit.    If you do not allow these
   cookies you may not be able to use or see these sharing tools.

 * PERFORMANCE COOKIES
   
   Switch Label label
   
   These cookies allow us to count visits and traffic sources so we can measure
   and improve the performance of our site. They help us to know which pages are
   the most and least popular and see how visitors move around the site.    All
   information these cookies collect is aggregated and therefore anonymous. If
   you do not allow these cookies we will not know when you have visited our
   site, and will not be able to monitor its performance.

 * TARGETING COOKIES
   
   Switch Label label
   
   These cookies may be set through our site by our advertising partners. They
   may be used by those companies to build a profile of your interests and show
   you relevant adverts on other sites.    They do not store directly personal
   information, but are based on uniquely identifying your browser and internet
   device. If you do not allow these cookies, you will experience less targeted
   advertising.

Back Button


PERFORMANCE COOKIES



Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
Switch Label label
Switch Label label
Switch Label label

Confirm My Choices

ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789-_~

x